Return on Equity (ROE)

The current Return on Equity (ROE) of 763.4% means that for every dollar of shareholder equity, bluebird bio generated $7.63 in net income over the past year—a measure of how efficiently the company uses investors’ capital to produce profit.

This figure is dramatically above the Healthcare sector median of 11.1%, placing the company in the 100th percentile among its peers. No trend data is available: the year-over-year change is listed as N/A, and the quarter-over-quarter change is also N/A, so no pattern of direction or consistency can be observed. The extreme level of ROE suggests the company is highly profitable relative to its equity base, but the complete absence of trend information leaves the sustainability of this performance unknown—creating ambiguity rather than a clear opportunity or risk. This metric alone neither supports nor contradicts the overall NEUTRAL verdict; the extraordinary ROE is a positive signal, but the lack of historical context prevents drawing a conclusive bullish or bearish stance, aligning with the neutral view.

Frequently Asked Questions

Closest Sector Peers